IgA1 protease fragment as carrier peptides
AssigneesMax-Planck-Gesellschaft zur Forderung Der Wissenschaffen E.V. Berlin, Pasteur Merieux Serums et Vaccins
InventorsMark Achtman, Monique Moreau
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending with an amino acid in any one of positions 40 to 104 or a homologous sequence, its use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide.
Claims18
1-25 (Canceled).
26:
- A conjugate comprising a peptide and an immunoreactive molecule, wherein the peptide has 40 to 200 residues and comprises an amino acid sequence having 40 or more amino acids that are identical or homologous to an amino acid sequence selected from the group consisting of amino acid sequences:
- (a) of SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (b) of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (c) of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (d) of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- and
- (e) of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.
27:
- The conjugate of claim 26, wherein the peptide comprises at least 40 amino acids of the amino acid sequence shown in SEQ ID NO 1, beginning with the amino acid residue in any one of the positions 1 to 5 and ending with an amino acid residue in any one of positions 40 to 104, or a homologous sequence.
28:
- The conjugate of claim 26, wherein the peptide comprises a sequence of at least 40 amino acids that is at least 85% identical to any one of the amino acid sequences of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4,or SEQ ID NO5.
29:
- The conjugate of claim 26, wherein the peptide comprises a sequence of at least 70 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of the positions 70 to 104.
30:
- The conjugate of claim 26, wherein the peptide comprises a sequence of at least 100 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of the positions 1 to 5 and ending with the amino acid residue in any one of the positions 100 to 104.
31:
- The conjugate of claim 26, wherein the peptide comprises the amino acid sequence of SEQ ID NO 1.
32:
- The conjugate of claim 26, wherein the peptide comprises an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO 1.
33:
- The conjugate of claim 26, wherein the peptide further comprises an additional cysteine residue.
34:
- The conjugate of claim 33, wherein the cysteine residue is located at one terminus of the peptide sequence.
35:
- The conjugate of claim 26, wherein the immunoreactive molecule is a polysaccharide.
36:
- The conjugate of claim 35, wherein the polysaccharide is Polysaccharide C of Neisseria meningitidis, Neisseria gonorrhoeae or Haemophilus influenzae.
37:
- The conjugate of claim 26, further comprising an additional cysteine residue in the peptide, a bifunctional linker and a polysaccharide, wherein the peptide is bonded to the linker via the thiol group of the cysteine and the polysaccharide is bonded to the other functional group of the linker via a hydroxy, carboxy, or amino group.
38:
- The conjugate of claim 26, wherein the conjugate comprises one mole of peptide per 50 to 1 moles of immunoreactive molecule.
39:
- A method of forming a conjugate, comprising linking a peptide to an immunoreactive molecule, thereby forming a peptide-immunoreactive molecule conjugate, wherein the peptide has 40 to 200 residues and comprises an amino acid sequence having 40 or more amino acids that are identical or homologous to an amino acid sequence selected from the group consisting of amino acid sequences:
- (a) of SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (b) of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (c) of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- (d) of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
- and
- (e) of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.
40:
- The method of claim 39, wherein the immunoreactive molecule is selected from the group of polysaccharides consisting of lipopolysaccharides, O-antigens, bacterial membrane polysaccharides, capsular membrane polysaccharides and fungal membrane polysaccharides.
41:
- The method of claim 39, wherein the immunoreactive molecule is Polysaccharide C of Neisseria meningitidis, Neisseria gonorrhoeae or Haemophilus influenzae.
42:
- A vaccine comprising the conjugate of claim 26 and a conventional carrier, excipient, or diluent.